On May 26, 2026, Terrance P. Coyne, who serves as Executive Vice President and Chief Financial Officer of Royalty Pharma plc (NASDAQ:RPRX), completed the sale of 64,399 Class A Ordinary Shares. These transactions amounted to approximately $3,476,116, with the shares being sold at a weighted average price of $53.9778 per share. The specific sale prices observed for these shares ranged between $53.64 and $54.63.
The timing of this divestiture is notable as it occurred when RPRX stock was trading close to its 52-week high of $54.74, following a substantial return of 69% over the past twelve months. The sale itself was structured indirectly through TPC RP EPA1 LLC and was conducted in accordance with a pre-arranged 10b5-1 trading plan that Mr. Coyne had established on February 24, 2026.
Following the completion of this transaction, reports indicate that TPC RP EPA1 LLC holds zero shares. However, it is important to note that Mr. Coyne maintains several other indirect and direct holdings in Royalty Pharma. These retained positions include 24,170 Class A Ordinary Shares held indirectly by his spouse’s IRA, 23,270 shares indirectly held by his own IRA, 1,450 shares indirectly held by his spouse, and an additional 1,500 Class A Ordinary Shares that he holds directly.
Furthermore, the reporting person has interests in limited partnerships. These holdings are exchangeable for a total of 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd, which can be exchanged for 1,807,277 Class A Ordinary Shares, subject to specific vesting conditions.
Beyond the executive activity, recent company developments provide insight into RPRX’s operational health. Royalty Pharma Plc announced a strong financial performance during the first quarter of 2026. The company reported double-digit growth across both its portfolio receipts and royalty receipts. Although specific figures for earnings per share (EPS) or revenue forecasts were not disclosed, these results point toward sustained and robust operational momentum within the firm.
The company also communicated a high degree of confidence in its capacity for long-term expansion. This projected growth is supported by two key factors: a diversified asset portfolio and strategic investments. While the stock price movement was observed, it was not the primary focus of these recent updates. Additionally, no analyst upgrades or downgrades were mentioned as part of these developments, emphasizing RPRX’s ongoing commitment to leveraging its assets for continued growth.
From a valuation perspective, an analysis conducted by InvestingPro suggests that the stock may appear overvalued at current price levels when compared against its calculated Fair Value. For investors seeking deeper insight into RPRX's valuation or comprehensive corporate analysis, detailed Pro Research Reports are available, covering RPRX and over 1,400 other US equities.
The market data for Royalty Pharma Plc shows the stock closing at 54.48, with a slight increase of 0.51 points (+0.95%) in trading activity. The after-hours price was recorded at 54.48, showing no change (0.00%).
Risks
- The stock is currently analyzed as potentially overvalued relative to its Fair Value by third-party analysis.
- Future valuations are subject to the continued strength of the company's diversified portfolio and strategic investments.
- Market perception remains a factor, given that the sale occurred near the 52-week high following substantial gains.
More from Insider Trading
Risks
- The stock is currently analyzed as potentially overvalued relative to its Fair Value by third-party analysis.
- Future valuations are subject to the continued strength of the company's diversified portfolio and strategic investments.
- Market perception remains a factor, given that the sale occurred near the 52-week high following substantial gains.